| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.3 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |